Open an account

Annovis Bio

ANVS · NYSE

$0.9783+$0.0183 (+1.91%)TodayMarket closed ·
Prev close $0.96

ANVS analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy2
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 6 analysts

Average $10.71 (+994.8% upside)

Low
$7.07
Now
$0.9783
High
$17.85

Upgrades and downgrades

The latest rating actions, newest first

ANVS analyst upgrades, downgrades and rating actions
FirmDateActionRating
Roth CapitalAug 28, 2026MaintainsBuy
Canaccord GenuityAug 18, 2026MaintainsBuy
Roth CapitalJul 8, 2026InitiatesBuy
Canaccord GenuityApr 14, 2026MaintainsBuy

The case for and against

Updated Oct 1, 2026

Bull case

Annovis Bio is viewed favorably because its lead candidate buntanetap is advancing through a Phase 3 early Alzheimer’s disease program with 6-month and 18-month components, and enrollment has completed with 850 patients, reducing execution risk ahead of key readouts expected in 1Q27 and 1Q28. The company also strengthened its balance sheet by extending runway through 2Q27 while reporting 2Q26 operating expenses of $14.4mn, below the $18.3mn estimate, which supports continued development without immediate funding pressure. Given the huge unmet need in Alzheimer’s disease, buntanetap’s intriguing mechanism of action, and additional pipeline assets with positive clinical signals and FDA alignment, the company appears significantly undervalued on a fundamental basis.

Bear case

Annovis Bio is a high-risk clinical-stage company whose negative outlook is driven by a very modest cash runway and the likely need for financing that could dilute shareholders. Its pipeline is concentrated in difficult-to-treat neurodegenerative diseases, including Alzheimer’s and Parkinson’s, where late-stage failure from weak efficacy, safety issues, or lack of FDA acceptance remains a major threat, even though early Alzheimer’s data showed statistical significance on Adas-Cog in the biomarker-positive mild AD population on 4/29/24. Although the FDA accepted the 6/18-month protocol on 1/7/25 and the trial was initiated on 2/5/25, enrollment completion is only expected in Spring-26, leaving substantial execution, regulatory, and commercialization risk.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.